Journey Medical (DERM) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Journey Medical (DERM) has outperformed PepGen (PEPG) over the past year, losing 21.2% versus a loss of 51.1%. Journey Medical is the larger company by market cap ($169.9 million vs $165.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | PEPG |
|---|---|---|
| Share price | $6.02 | $2.39 |
| Market cap | $169.91M | $165.31M |
| 1-day change | +1.18% | -0.42% |
| YTD return | -22.83% | -63.13% |
| 1-year return | -21.19% | -51.12% |
| EPS (TTM) | $-0.22 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $7.80 |
| 52-week low | $4.31 | $1.31 |
| Distance from 52-week high | -37.00% | -69.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +128.41% | +326.36% |
| Average volume | 182.16K | 971.65K |
| Shares outstanding | 22.22M | 69.17M |
| Employees | 58 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DERM has outperformed PEPG by 29.9 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
DERM vs PEPG FAQ
Which is bigger, Journey Medical or PepGen?
Journey Medical (DERM) is larger, with a market capitalization of $169.91M compared with $165.31M for PepGen (PEPG).
Which stock has performed better over the past year, DERM or PEPG?
DERM returned -21.19% over the past 12 months, compared with -51.12% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.